• Something wrong with this record ?

A Subset of New Platinum Antitumor Agents Kills Cells by a Multimodal Mechanism of Action Also Involving Changes in the Organization of the Microtubule Cytoskeleton

H. Kostrhunova, J. Zajac, V. Novohradsky, J. Kasparkova, J. Malina, JR. Aldrich-Wright, E. Petruzzella, R. Sirota, D. Gibson, V. Brabec,

. 2019 ; 62 (10) : 5176-5190. [pub] 20190509

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc20023939

The substitution inert platinum agent [Pt(1 S,2 S-diaminocyclohexane)(5,6-dimethyl-1,10-phenanthroline)]2+ (56MeSS, 5) is a potent cytotoxic metallodrug. In contrast to conventional cisplatin or oxaliplatin, the mechanism of action (MoA) of 5 is fundamentally different. However, details of the mechanism by which the 5,6-dimethyl-1,10-phenanthroline ligand contributes to the cytotoxicity of 5 and its derivatives have not been sufficiently clarified so far. Here, we show that 5 and its Pt(IV) derivatives exhibit an intriguing potency in the triple-negative breast cancer cells MDA-MB-231. Moreover, we show that the Pt(IV) derivatives of 5 act by multimodal MoA resulting in the global biological effects, that is, they damage nuclear DNA, reduce the mitochondrial membrane potential, induce the epigenetic processes, and last but not least, the data provide evidence that changes in the organization of cytoskeleton networks are functionally important for 5 and its derivatives, in contrast to clinically used platinum cytostatics, to kill cancer cells.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023939
003      
CZ-PrNML
005      
20201214131845.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acs.jmedchem.9b00489 $2 doi
035    __
$a (PubMed)31030506
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kostrhunova, Hana $u Czech Academy of Sciences , Institute of Biophysics , Kralovopolska 135 , CZ-61265 Brno , Czech Republic.
245    12
$a A Subset of New Platinum Antitumor Agents Kills Cells by a Multimodal Mechanism of Action Also Involving Changes in the Organization of the Microtubule Cytoskeleton / $c H. Kostrhunova, J. Zajac, V. Novohradsky, J. Kasparkova, J. Malina, JR. Aldrich-Wright, E. Petruzzella, R. Sirota, D. Gibson, V. Brabec,
520    9_
$a The substitution inert platinum agent [Pt(1 S,2 S-diaminocyclohexane)(5,6-dimethyl-1,10-phenanthroline)]2+ (56MeSS, 5) is a potent cytotoxic metallodrug. In contrast to conventional cisplatin or oxaliplatin, the mechanism of action (MoA) of 5 is fundamentally different. However, details of the mechanism by which the 5,6-dimethyl-1,10-phenanthroline ligand contributes to the cytotoxicity of 5 and its derivatives have not been sufficiently clarified so far. Here, we show that 5 and its Pt(IV) derivatives exhibit an intriguing potency in the triple-negative breast cancer cells MDA-MB-231. Moreover, we show that the Pt(IV) derivatives of 5 act by multimodal MoA resulting in the global biological effects, that is, they damage nuclear DNA, reduce the mitochondrial membrane potential, induce the epigenetic processes, and last but not least, the data provide evidence that changes in the organization of cytoskeleton networks are functionally important for 5 and its derivatives, in contrast to clinically used platinum cytostatics, to kill cancer cells.
650    _2
$a aktiny $x antagonisté a inhibitory $7 D000199
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x chemická syntéza $x metabolismus $x farmakologie $7 D000970
650    _2
$a CHO buňky $7 D016466
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a křečci praví $7 D006224
650    _2
$a Cricetulus $7 D003412
650    _2
$a cytoskelet $x účinky léků $7 D003599
650    _2
$a DNA nádorová $x účinky léků $7 D004273
650    _2
$a screeningové testy protinádorových léčiv $7 D004354
650    _2
$a epigeneze genetická $x účinky léků $7 D044127
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a ligandy $7 D008024
650    _2
$a mikrotubuly $x účinky léků $7 D008870
650    _2
$a organoplatinové sloučeniny $x chemická syntéza $x metabolismus $x farmakologie $7 D009944
650    _2
$a triple-negativní karcinom prsu $x farmakoterapie $7 D064726
650    _2
$a modulátory tubulinu $x farmakologie $7 D050257
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Zajac, Juraj $u Czech Academy of Sciences , Institute of Biophysics , Kralovopolska 135 , CZ-61265 Brno , Czech Republic.
700    1_
$a Novohradsky, Vojtech $u Czech Academy of Sciences , Institute of Biophysics , Kralovopolska 135 , CZ-61265 Brno , Czech Republic.
700    1_
$a Kasparkova, Jana $u Czech Academy of Sciences , Institute of Biophysics , Kralovopolska 135 , CZ-61265 Brno , Czech Republic.
700    1_
$a Malina, Jaroslav $u Czech Academy of Sciences , Institute of Biophysics , Kralovopolska 135 , CZ-61265 Brno , Czech Republic.
700    1_
$a Aldrich-Wright, Janice R $u School of Science and Health , Western Sydney University , Penrith South DC 1797 , NSW , Australia.
700    1_
$a Petruzzella, Emanuele $u Institute for Drug Research, School of Pharmacy , The Hebrew University , Jerusalem 91120 , Israel.
700    1_
$a Sirota, Roman $u Institute for Drug Research, School of Pharmacy , The Hebrew University , Jerusalem 91120 , Israel.
700    1_
$a Gibson, Dan $u Institute for Drug Research, School of Pharmacy , The Hebrew University , Jerusalem 91120 , Israel.
700    1_
$a Brabec, Viktor $u Czech Academy of Sciences , Institute of Biophysics , Kralovopolska 135 , CZ-61265 Brno , Czech Republic.
773    0_
$w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 62, č. 10 (2019), s. 5176-5190
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31030506 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214131845 $b ABA008
999    __
$a ok $b bmc $g 1596258 $s 1114615
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 62 $c 10 $d 5176-5190 $e 20190509 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Archiving options